RESMED, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 177.5 USD | +2.11% |
|
-6.28% | +3.25% |
| Apr. 17 | Wall St set for higher open on megacaps boost; earnings, Fed comments on tap | RE |
| Apr. 01 | Needham Adjusts ResMed's Price Target to $224 From $180, Maintains Buy Rating | MT |
Financials (USD)
| Sales 2024 * | 4.64B | Sales 2025 * | 4.96B | Capitalization | 25.53B |
|---|---|---|---|---|---|
| Net income 2024 * | 972M | Net income 2025 * | 1.17B | EV / Sales 2024 * | 5.64 x |
| Net Debt 2024 * | 609M | Net cash position 2025 * | 260M | EV / Sales 2025 * | 5.09 x |
| P/E ratio 2024 * |
26.6
x | P/E ratio 2025 * |
22.7
x | Employees | 10,140 |
| Yield 2024 * |
1.13% | Yield 2025 * |
1.22% | Free-Float | 77.08% |
More Fundamentals
* Assessed data
More news
Latest transcript on ResMed, Inc.
More recommendations
More press releases
More news
| 1 day | -5.97% | ||
| 1 week | -10.30% | ||
| Current month | -12.22% | ||
| 1 month | -8.53% | ||
| 3 months | +1.83% | ||
| 6 months | +22.55% | ||
| Current year | +1.05% |
1 week
172.19
189.41
1 month
172.19198.54
Current year
164.12198.54
1 year
132.24243.52
3 years
132.24301.34
5 years
98.31301.34
10 years
45.74301.34
| Managers | Title | Age | Since |
|---|---|---|---|
Mick Farrell
CEO | Chief Executive Officer | 51 | 00-08-31 |
Peter Farrell
FOU | Founder | 81 | 89-05-31 |
Leo Toole
DFI | Director of Finance/CFO | 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mick Farrell
CEO | Chief Executive Officer | 51 | 00-08-31 |
Ron Taylor
BRD | Director/Board Member | 76 | 04-12-31 |
Peter Farrell
FOU | Founder | 81 | 89-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.09% | 18 M€ | +2.91% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 177.6 | +2.17% | 640 792 |
| 24-04-17 | 173.8 | -5.97% | 3,005,122 |
| 24-04-16 | 184.9 | -0.12% | 411,889 |
| 24-04-15 | 185.1 | -0.41% | 605,411 |
| 24-04-12 | 185.9 | -1.93% | 659,893 |
Delayed Quote Nyse, April 17, 2024 at 04:00 pm EDT
More quotes
ResMed, Inc. specializes in designing, manufacturing and marketing respiratory disorders diagnosis, treatments and management (primarily sleep respiratory disorders). Net sales break down by family of products as follows:
- medical devices (50.4%);
- masks (37.9%);
- software as a service (11.7%).
At the end of June 2021, the group had 6 production sites located in the United States (2), Australia, China, Singapore and Malaysia.
The United States accounts for 61.4% of net sales.
Calendar
2024-04-25
- Q3 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
173.8
USD
Average target price
206.1
USD
Spread / Average Target
+18.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.05% | 25.53B | |
| +3.10% | 209B | |
| +3.48% | 177B | |
| +10.91% | 133B | |
| +17.56% | 99.89B | |
| -0.99% | 61.83B | |
| +14.41% | 52.51B | |
| -6.21% | 45.54B | |
| -3.22% | 39.43B | |
| +10.18% | 38.87B |
- Stock Market
- Equities
- RMD Stock
